Contact us

Welcome to
Shield Therapeutics

Find out about us

Our People

Driven by and committed to our goals

Our Investors

Delivering more value to our shareholders

Careers

Offering opportunity, ambition and development

Specialty pharmaceutical company

Providing solutions to unmet medical needs.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.

Find out more

Our Products

A treatment for iron deficiency anaemia

Our lead product, Feraccru®, is a novel oral treatment for iron deficiency anaemia (IDA) which, following receipt of marketing authorisation in early 2016, is now commercially available for use initially in patients with inflammatory bowel disease
associated IDA.

Find out more

PM Society Awards Gold winner for Events & Exhibitions

Awarded Company of the Year at the 2016 Bionow Awards

11 Apr 2018

Preliminary Results for the Year Ended 31 December…

Shield Therapeutics plc (LSE:STX) today announces its preliminary Group results for the year ended 31 December 2017. For full details…

6 Apr 2018

Shield confirms appointment of Non-Executive Director

For further details please see the press release attached. STX_Confirms NED appointment

6 Apr 2018

Shield announces results from it’s Pre-Submission meeting with…

Shield Therapeutics announces results from it's Pre-Submission meeting with the FDA and confirms plans to submit a New Drug Application…
View more news articles

London, UK

120 New Cavendish Street
London
W1W 6XX

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Munich, Germany

München 5 Höfe
Theatinerstrasse 11
DE- 80333 München

t+49 (0) 89 710 42 2246

einfo.de@shieldtx.com

© 2018 Shield Therapeutics.